uniQure (NASDAQ:QURE) Insider Sells $431,228.16 in Stock

Posted by Brenda Bartman on Jun 15th, 2026

uniQure N.V. (NASDAQ:QURE – Get Free Report) insider Kylie O’keefe sold 15,936 shares of uniQure stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $27.06, for a total transaction of $431,228.16. Following the transaction, the insider directly owned 108,864 shares of the company’s stock, valued at approximately $2,945,859.84. This represents a 12.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

uniQure Stock Performance

uniQure stock opened at $27.57 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market capitalization of $1.74 billion, a P/E ratio of -7.92 and a beta of 0.98. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The company’s 50-day moving average is $22.52 and its 200 day moving average is $21.76.

uniQure (NASDAQ:QURE – Get Free Report) last announced its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. Research analysts forecast that uniQure N.V. will post -3.64 EPS for the current year.

Hedge Funds Weigh In On uniQure

A number of hedge funds and other institutional investors have recently modified their holdings of QURE. Torren Management LLC purchased a new position in uniQure during the fourth quarter valued at approximately $28,000. Jones Financial Companies Lllp lifted its holdings in uniQure by 509.0% during the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares during the period. IFP Advisors Inc bought a new stake in uniQure during the 4th quarter valued at $48,000. Smartleaf Asset Management LLC bought a new stake in uniQure during the 4th quarter valued at $48,000. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of uniQure in the 3rd quarter valued at $50,000. 78.83% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. The Goldman Sachs Group upped their price target on shares of uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a report on Monday, April 20th. Chardan Capital raised their price target on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, April 30th. Leerink Partners reiterated an “outperform” rating and set a $35.00 price objective on shares of uniQure in a report on Monday, March 2nd. Finally, Sanford C. Bernstein cut shares of uniQure to a “market perform” rating in a research report on Tuesday, March 3rd. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.83.

View Our Latest Stock Analysis on QURE

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

Negative Sentiment: A cluster of insiders sold shares in recent filings, including directors Robert Gut, Madhavan Balachandran, Rachelle Suzanne Jacques, Jack Kaye, Leonard E. Post, Jeremy P. Springhorn, and David D. Meek, along with insider Kylie O’keefe. The transactions totaled a meaningful reduction in ownership across the group, increasing focus on insider confidence. Article: UniQure Rocked by Wave of High-Level Insider Stock Sales
Neutral Sentiment: Several of the sales were made under pre-arranged Rule 10b5-1 trading plans, which can lessen the bearish signal because the trades may have been scheduled in advance rather than reflecting a sudden change in outlook.
Neutral Sentiment: The stock has already been trending above its 50-day and 200-day moving averages, so some of the selling may simply reflect profit-taking after a strong move rather than a deterioration in the company’s fundamentals.

About uniQure

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.